Daratumumab (anti-CD38)
Daratumumab (anti-CD38) (A2027-GRP)
Products
Description
Daratumumab (anti-CD38) is a recombinant monoclonal antibody to CD38. Daratumumab is an investigational anti-cancer drug which is indicated for the treatment of adult patients with multiple myeloma. MW =145.4 kDa.
Specifications
| Manufacturer | Selleck Chemicals LLC |
|---|---|
| Manufacturer Cat# | A2027 |
| Target | CD markers |